IBVIS
LIVE

Serial Number

79296446

Owner

Veritas In Silico Inc.

Attorney

Sean K. Owens

Filing Date

Aug 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

IBVIS Trademark

Serial Number: 79296446 • Registration: 6741536

IBVIS is a trademark filed by Veritas In Silico Inc. on August 11, 2020. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Veritas In Silico Inc. (3 trademarks)

1-11-1, Nishi-Gotanda,

Entity Type: 03

Trademark Details

Filing Date

August 11, 2020

Registration Date

May 31, 2022

Published for Opposition

March 15, 2022

Goods & Services

Designing of machines, apparatus, instruments, machine parts, and systems composed of such machines, apparatus and instruments; pharmaceutical, medicine, chemical and engineering design services; computer software design, computer programming, and maintenance of computer software; designing, programming and maintenance of computer software having artificial intelligence functionality; computer software design, computer programming, and maintenance of computer software for use in scientific and technical analysis of data from artificial intelligence; computer software design, computer programming, and maintenance of computer software for use in analysis, testing, screening, designing, development or research on nucleic acids, pharmaceuticals or chemicals; computer software design, computer programming, and maintenance of computer software for use in drug discovery screening; computer software design, computer programming, and maintenance of computer software for analyzing and assaying messenger RNA (mRNA) substructures; computer program design, computer programming, and maintenance of computer program for databases; computer software design, computer programming, and maintenance of computer software for use in genome research or the development of consumer health products, treatments, pharmaceutical preparations, diagnostic instruments or foodstuffs; information processing using computers, namely, providing online nondownloadable software for processing of data regarding RNA and RNA-compound interaction by computers for use in developing new drugs; technical advice relating to computers, computers for automobiles and other computers for industrial machines requiring highly specialized knowledge, skills and experiences for proper operation; scientific and technical research consultancy in the field of life information science, nucleic acids diagnosis and drug discovery, and research and development relating thereto; analysis and research in the field of life information science and technology, namely, analysis and research on target identification and validation, and prediction of structure and function of proteins and nucleic acids; laboratory research and development of new products for others in the field of life information science, nucleic acids diagnosis and drug discovery; scientific and technological services, namely, biochemical and biological testing, inspection of medical and chemical goods for quality control purposes, efficacy and quality analysis of medical and chemical products, medical and chemical product development and research; chemical analysis and screening on chemicals, namely, chemical product quality evaluation; screening on pharmaceuticals, namely, pharmaceutical product evaluation; scientific research, testing and analysis in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicines, chemicals and engineering; research services in the field of biological science, namely, isolation, purification, analysis, screening and research on DNA, RNA and other biological materials; quality assessment services, namely, quality control and evaluation for others; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; development and research on pharmaceuticals targeting messenger RNA (mRNA) substructures, and providing information and consultancy relating thereto; Scientific and technological services, namely, testing, inspection, analysis, surveying, development and research on small molecule compounds, antisense oligonucleotides and compounds, and providing information and consultancy relating thereto; analysis, surveying and development of pharmaceuticals, and providing information and consultancy relating thereto; testing, inspection and research for drug development and medical research purposes, and providing information and consultancy relating thereto; testing and research on biotechnology and providing information and consultancy relating thereto; medical and biological research in the nature of genomic experiments, analyses, research, assays, testing, inspection and detection of medical and biological products for efficacy and quality evaluation; consultancy, advice and providing information on medical and biological research in the nature of genomic experiments, analyses, research, assays, testing, inspection and detection of medical and biological products for efficacy and quality evaluation; testing, surveying, research and data analysis for research purposes in the field of biomedicine, genome biology, pharmacogenomics, diagnostics, clinical trials or bioengineering; testing, inspection and research of chemicals or reagents; research and development of vaccines and medicines; research and development of vaccines and medicines; consultancy and providing information on testing, inspection and research of pharmaceuticals, chemicals, reagents, cosmetics or foodstuffs; conducting clinical trials for others on pharmaceuticals; research on building construction or city planning; testing or research on prevention of pollution; testing or research on electricity; testing or research on civil engineering; testing, inspection or research on agriculture, livestock breeding or fisheries; testing the functionality of and research on machines, apparatus and instruments; rental of measuring apparatus; rental of computers; providing computer programs on data networks, namely, providing temporary use of non-downloadable computer software for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; cloud computing, namely, providing temporary use of on-line non-downloadable cloud computing software for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; software as a service (SaaS) services featuring software for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; electronic storage services for archiving electronic data; providing electronic data server storage services on the internet; providing temporary use of non-downloadable computer software having artificial intelligence functionality on data networks for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; providing temporary use of online non-downloadable computer software for analysis of science and technology data based on artificial intelligence (AI) technology; providing temporary use of online non-downloadable computer software for use in analysis, testing, screening, designing, development or research of nucleic acids, pharmaceuticals or chemicals; providing temporary use of online non-downloadable computer software for use in drug discovery screening; providing temporary use of online non-downloadable computer programs on data networks for analyzing and assaying messenger RNA, or mRNA, substructures; providing temporary use of online non-downloadable computer programs for creating, accessing, managing and searching databases; providing temporary use of online non-downloadable computer software for use in genome research and the development of consumer health products, treatments, pharmaceutical preparations, diagnostic instruments or foodstuffs; rental of laboratory apparatus and instruments

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 20, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 20, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 20, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 20, 2024 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 11, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 11, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 11, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 11, 2022 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 10, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 15, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 15, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 31, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 31, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
May 31, 2022 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 10, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2022 OPNR
NOTIFICATION PROCESSED BY IB
Mar 21, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 15, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 23, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 23, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 23, 2022 NONP
ASSIGNED TO LIE
Feb 6, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 4, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 4, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 4, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 4, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 4, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2022 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jul 27, 2021 GPRN
PRIORITY ACTION E-MAILED
Jul 27, 2021 GPRA
PRIORITY ACTION WRITTEN
Jul 27, 2021 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 23, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 23, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 23, 2021 TROA
REFUSAL PROCESSED BY IB
Jan 15, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 29, 2020 RFCS
REFUSAL PROCESSED BY MPU
Dec 28, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 15, 2020 RFCR
NON-FINAL ACTION WRITTEN
Dec 14, 2020 CNRT
ASSIGNED TO EXAMINER
Dec 6, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 30, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 22, 2020 REPR